These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 23199968)

  • 1. Human papillomavirus vaccines--immune responses.
    Stanley M; Pinto LA; Trimble C
    Vaccine; 2012 Nov; 30 Suppl 5():F83-7. PubMed ID: 23199968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
    Stanley M; Lowy DR; Frazer I
    Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
    Stanley M; Gissmann L; Nardelli-Haefliger D
    Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring serum antibody to human papillomavirus following infection or vaccination.
    Frazer IH
    Gynecol Oncol; 2010 Jun; 118(1 Suppl):S8-11. PubMed ID: 20494221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.
    Berg MG; Adams RJ; Gambhira R; Siracusa MC; Scott AL; Roden RB; Ketner G
    Clin Vaccine Immunol; 2014 Sep; 21(9):1224-31. PubMed ID: 24990902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.
    Luxembourg A; Bautista O; Moeller E; Ritter M; Chen J
    Contemp Clin Trials; 2015 May; 42():18-25. PubMed ID: 25749310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine.
    Nardelli-Haefliger D; Lurati F; Wirthner D; Spertini F; Schiller JT; Lowy DR; Ponci F; De Grandi P
    Vaccine; 2005 May; 23(28):3634-41. PubMed ID: 15882523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme.
    Mollers M; Vossen JM; Scherpenisse M; van der Klis FR; Meijer CJ; de Melker HE
    J Med Virol; 2013 Aug; 85(8):1379-85. PubMed ID: 23722396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination.
    Stern PL
    J Clin Virol; 2005 Mar; 32 Suppl 1():S72-81. PubMed ID: 15753015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
    Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
    Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy.
    Bhat P; Mattarollo SR; Gosmann C; Frazer IH; Leggatt GR
    Immunol Rev; 2011 Jan; 239(1):85-98. PubMed ID: 21198666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune responses to human papilloma viruses.
    Stanley MA
    Indian J Med Res; 2009 Sep; 130(3):266-76. PubMed ID: 19901436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
    Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
    Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions.
    Chen J; Ni G; Liu XS
    Cell Immunol; 2011; 269(1):5-9. PubMed ID: 21477796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Papillomavirus virus-like particles as anticancer vaccines.
    Da Silva DM; Velders MP; Rudolf MP; Schiller JT; Kast WM
    Curr Opin Mol Ther; 1999 Feb; 1(1):82-8. PubMed ID: 11249689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Explanations for the high potency of HPV prophylactic vaccines.
    Schiller J; Lowy D
    Vaccine; 2018 Aug; 36(32 Pt A):4768-4773. PubMed ID: 29325819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlating immunity with protection for HPV infection.
    Frazer I
    Int J Infect Dis; 2007 Nov; 11 Suppl 2():S10-6. PubMed ID: 18162240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.
    Handisurya A; Schellenbacher C; Haitel A; Senger T; Kirnbauer R
    Br J Cancer; 2016 Feb; 114(4):409-16. PubMed ID: 26867163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.